Article Text

Download PDFPDF

Efficacy of licofelone in dogs with clinical osteoarthritis
  1. M. Moreau, MSc1,
  2. B. Lussier, DMV, MSc, DACVS1,
  3. M. Doucet, DMV, DVSc, DACVIM, DACVCP2,
  4. G. Vincent, PhD3,
  5. J. Martel-Pelletier, PhD3 and
  6. J-P. Pelletier, MD3
  1. 1 Companion Animal Research Group, Veterinary Teaching Hospital Centre
  2. 2 Department of Biomedicine, Faculty of Veterinary Medicine, University of Montreal, PO Box 5000, St Hyacinthe, Quebec, J2S 7C6, Canada
  3. 3 Osteoarthritis Research Unit, University of Montreal Hospital Centre, Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec, H2L 4M1, Canada
  1. Correspondence to Professor Pelletier


To evaluate the effect of licofelone, an arachidonic acid substrate with combined inhibitory activity against 5-lipoxygenase and cyclooxygenases 1 and 2, a double-blind, randomised and placebo-controlled study was conducted in 33 client-owned dogs that were lame owing to hindlimb osteoarthritis. Seventeen of the dogs received a placebo and 16 were treated with 2·5 mg/kg licofelone twice a day for 28 days. The dogs' lameness was assessed on a visual analogue scale (vas), and by force plate analyses at baseline and 14 and 28 days after starting the treatment. After 14 days the mean (se) change in peak vertical force in the licofelone-treated dogs (1·7 [0·8] per cent bodyweight) was significantly greater (P<0·05) than in the placebo-treated dogs (−0·3 [0·6] per cent bodyweight), and after 28 days the difference had increased. In contrast, the dogs' lameness, as assessed by the vas values, had decreased significantly over baseline in both the treated and control groups.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.